Your browser doesn't support javascript.
Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine.
Mahmoud, Sally; Ganesan, Subhashini; Sharif-Askari, Narjes Saheb; Cantarutti, Flavia; Wilson, Hannah; Ogrodzki, Pauline; Halwani, Rabih; Alkaabi, Nawal; Zaher, Walid Abbas.
  • Mahmoud S; Biogenix Lab, Abu Dhabi, UAE.
  • Ganesan S; G42 Healthcare, Abu Dhabi, UAE.
  • Sharif-Askari NS; IROS (Insights Research Organization and Solutions), Abu Dhabi, UAE.
  • Cantarutti F; College of Medicine, University of Sharjah, Sharjah, UAE.
  • Wilson H; G42 Healthcare, Abu Dhabi, UAE.
  • Ogrodzki P; IROS (Insights Research Organization and Solutions), Abu Dhabi, UAE.
  • Halwani R; IROS (Insights Research Organization and Solutions), Abu Dhabi, UAE.
  • Alkaabi N; G42 Healthcare, Abu Dhabi, UAE.
  • Zaher WA; College of Medicine, University of Sharjah, Sharjah, UAE.
Curr Med Res Opin ; 38(12): 2069-2075, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2087496
ABSTRACT

BACKGROUND:

Breakthrough infections post-COVID-19 vaccination occur with the emerging variants of the SARS-CoV virus which might be either due to the newer variants escaping immune response or the waning of antibodies over time. However, there is lack of long-term follow-up evidence on the waning of immune response following inactivated COVID-19 vaccine.

METHODS:

A retrospective, observational study was conducted on serum samples of individuals who had received two doses of BBIBP-CorV vaccine. Individual's antibody responses were evaluated based on IgG anti-S and neutralizing antibodies measurements. Antibody samples were categorized into four groups, defined by the time interval from the individual's receipt of the BBIBP-CorV vaccine <30 days, 30-90 days, 91-180 days and >180 days.

RESULTS:

A total of 6668 serum samples from inactivated BBIBP-CorV vaccine recipients were analyzed for IgG anti-S and neutralizing antibodies. 571 (8.6%) samples were tested during the first 29 days interval post vaccination, 3642 (54.6%) were tested during 30-90 days interval, 2173 (32.6%) samples were tested during 91 to 180 days interval and 282(4.2%) were tested at >180 days interval post vaccination. We found that more than 50% of the individuals had antibody titers below the average cut-off range at the 91-180 days interval post vaccination. Older age (>60 years), male gender, chronic kidney disease, hypertension, immunodeficiencies and increased interval post vaccination emerged as independent risk factors associated with lower immune response.

CONCLUSION:

Inactivated BBIBP-CorV vaccine recipients, based on age, gender and associated comorbid conditions might need booster doses at an earlier interval than the currently followed six months interval.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines / Variants Limits: Humans / Infant / Male Language: English Journal: Curr Med Res Opin Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines / Variants Limits: Humans / Infant / Male Language: English Journal: Curr Med Res Opin Year: 2022 Document Type: Article